Key result
Chronic Fatigue Syndrome is linked to ~117% higher Borna Disease Virus immunoreactivity versus healthy controls.
Why the study?
Does serum immune reactivity to Borna Disease Virus differ between patients with Chronic Fatigue Syndrome and healthy controls?
Case-Control (n=110)
Does serum immune reactivity to Borna Disease Virus differ between patients with Chronic Fatigue Syndrome and healthy controls?
A small number of CFS patients show immunoreactivity to multiple Borna Disease Virus proteins, though the overall prevalence and pathogenic role remain undefined.
Answers are grounded in this paper and cite their sources.
Low Borna Disease Virus immunoreactivity prevalence in CFS similar to controls; hypothesis-generating and should not yet change practice.
SummaryBornavirus is a member of a newly recognized virus family, Bornaviridae, and is neurotropic for a wide range of animal species, including birds, rodents, horses, and humans. Although little is known about its mode of transmission and it has not been clearly linked to any human disease, an association between borna viruses and neuro-psychiatric disorders has been suggested. Several researchers have also isolated this organism from patients who meet the clinical criteria for the Chronic Fatigue Syndrome (CFS). However, due to non-standardization of assay protocols, lack of a large study population and the possibility of contamination in certain laboratory settings, the true prevalence of Bornaviral proteins and their possible role in the pathogenesis of at least a subgroup of CFS patients remains undefined. We analyzed the serum immune reactivity to Borna Disease Virus (BDV) in 77 CFS patients and in 33 healthy normal controls using an ELISA based assay of 3 different recombinant BDV proteins. Of the 6 samples that displayed immunoreactivity to 2 or more BDV proteins, 5 were from patients (83.3%). Two samples, both from CFS patients, displayed immunoreactivity to 3 BDV proteins.
No takes yet. Share an insight, caveat, or question.
Susan Levine (1999) conducted a case-control in Chronic Fatigue Syndrome (CFS) (n=110). Chronic Fatigue Syndrome (CFS) vs. Healthy normal controls was evaluated on Immunoreactivity to 2 or more BDV proteins. Serum immunoreactivity to 2 or more Borna Disease Virus proteins was detected in 6.5% (5/77) of patients with Chronic Fatigue Syndrome compared to 3.0% (1/33) of healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: